Innocan Pharma Showcases Innovations at Upcoming Conference
Innocan Pharma's Upcoming Presentation
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is gearing up for a significant event at the ThinkEquity Conference. Scheduled to take place at the Mandarin Oriental in New York City, this annual gathering will bring together leading institutional investors, analysts, and emerging growth companies.
Conference Highlights
The ThinkEquity Conference is renowned for facilitating insightful discussions and interactions between companies and investors. It serves as a platform for Innocan Pharma to share critical business updates and explore fresh market opportunities.
Presentation Details
At the conference, Innocan Pharma will showcase its strategies and innovations during a dedicated presentation at 9:30 a.m. New York time in the Boardroom. The session aims to highlight the company's ambitious regulatory milestones in both Human and Animal Health sectors.
Focus on Innovative Pain Management
One of the focal points of Innocan Pharma's presentation will be its LPT-CBD innovative injectable platform designed for chronic pain management. This advanced therapeutic approach represents a significant stride toward a more effective non-opioid solution for patients dealing with persistent pain.
Key Presenters
Innocan's presentation team will include prominent figures such as Iris Bincovich, the CEO, and Roni Kamhi, the COO. They will be joined by Dr. Joseph V. Pergolizzi, Jr., M.D., a highly respected expert in pain management and pharmacology.
Understanding Dr. Pergolizzi's Background
Dr. Pergolizzi currently serves as a Senior Partner at Naples Anesthesia and Pain Associates and as the Chief Operating Officer at NEMA Research Inc. His expertise encompasses numerous aspects of medicine and drug development, making him an invaluable asset to Innocan Pharma's leadership team.
About ThinkEquity
Founded by a team of professionals with over a decade of collaborative experience, ThinkEquity is a boutique investment bank. They have successfully financed more than $50 billion across various sectors through public and private capital raises, restructurings, and mergers and acquisitions. Previous conferences have attracted hundreds of attendees and featured numerous presentations, solidifying its position as a key event in the investment landscape.
Innocan Pharma's Innovative Approach
Innocan Pharma stands out in the pharmaceutical and wellness sectors for its groundbreaking contributions. The company has developed a CBD-loaded liposome drug delivery platform that offers precise dosing, prolonged release of synthetic CBD, and effective pain management without the drawbacks of opioids. Furthermore, Innocan is broadening its horizons in the wellness industry with a portfolio of high-performance beauty products aimed at promoting a healthier lifestyle.
Contact Information
For further details about Innocan Pharma or inquiries related to the conference, the company can be reached through the following contacts:
Innocan Pharma Corporation
Iris Bincovich, CEO
+1 516-210-4025
+972-54-3012842
+44 203-769-9377
info@innocanpharma.com
Frequently Asked Questions
What is the ThinkEquity Conference?
The ThinkEquity Conference is an annual event that connects institutional investors with growth companies for presentations and networking opportunities.
When does Innocan Pharma's presentation take place?
Innocan Pharma will present at 9:30 a.m. New York time at the conference.
Who are Innocan Pharma's presenters at the conference?
The presentation will feature Iris Bincovich, Roni Kamhi, and Dr. Joseph V. Pergolizzi, Jr., among others.
What is Innocan Pharma's focus in chronic pain management?
Innocan Pharma aims to introduce its innovative LPT-CBD injectable platform as a non-opioid treatment for chronic pain management.
How can I contact Innocan Pharma for more information?
You can reach Innocan Pharma by email at info@innocanpharma.com or through the given phone numbers.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
